Ark Therapeutics Group PLC Re Agreement (6485O)
15 October 2012 - 5:00PM
UK Regulatory
TIDMAKT
RNS Number : 6485O
Ark Therapeutics Group PLC
15 October 2012
Laurantis Pharma and Ark Therapeutics Sign Manufacturing
Agreement for Production of Lymfactin(TM) Investigational Treatment
for Breast Cancer-Associated Lymphedema
15 October 2012, London, UK Ark Therapeutics has been selected
to manufacture and supply Lymfactin(TM) to Laurantis Pharma under a
conditional agreement announced today by the Finland-based
companies. The agreement is subject to Laurantis receiving
regulatory approval to commence its phase I clinical trial.
Specific terms of the agreement are not disclosed. Lymfactin(TM)
uses an adenoviral vector to deliver vascular endothelial growth
factor (VEGF-C) during transplantation of lymph nodes in order to
avoid lymphedema.
The phase I clinical trial using Lymfactin(TM) to treat breast
cancer-associated lymphedema is targeted to begin in 2013, and will
recruit patients in the USA and Finland. Breast cancer-associated
lymphedema is the most common form of secondary lymphedema,
occurring in approximately 20% of breast cancer patients who
undergo axillary lymph node dissection. The incidence is even
higher in those who also receive radiotherapy, and this
complication may even occur in those who undergo a lymph node
biopsy as part of treatment. No therapeutic treatment currently
exists to treat this disease.
In the US, approximately 110,000 patients are living with breast
cancer-associated lymphedema, and nearly 15,000 new patients
develop the complication each year. The number of lymphedema
patients in Europe is estimated to be roughly the same as in the
US.
For further information:
Ark Therapeutics Group plc Tel: +44 (0)20 7388 7722
Dr David Venables, CEO
Iain Ross, Chairman
Laurantis Pharma Oy Tel: +1 202 422-6999
David Sheon
FTI Consulting Tel: +44 (0)20 7831 3113
Ben Atwell
Susan Stuart
About Laurantis Pharma Oy
Based in Turku, Finland, Laurantis is a privately held
clinical-stage biotechnology company with a broad portfolio of
first-in-class products based on two proprietary technologies. The
Company's pipeline includes proprietary and patent-protected
formulations and applications of cis-urocanic acid, a locally
acting anti-inflammatory and anti-proliferative agent for the
treatment of Atopic Dermatitis, Dry Eye, Interstitial Cystitis, and
Bladder Cancer. Laurantis is also developing Lymfactin(TM), a
vascular endothelial growth factor C (VEGF-C) in an adenoviral
vector, as a gene therapy product for the treatment of secondary
lymphedema.
About Ark Therapeutics Group plc
Ark Therapeutics Group plc is a leading viral product focused
contract development and manufacturing services company with
world-class viral research, development and GMP manufacturing
operations in Finland and the UK. Ark's business model is to offer
product development and GMP manufacturing contract services for
viral products, including the areas of viral mediated gene therapy,
oncolytic viral vaccines, live and attenuated viral vaccines, viral
vectored vaccines and virus like particles. Ark's capabilities span
from translational research through preclinical and clinical
product development, in addition to process and analytical
development, GMP manufacture and sterile filling from pre-clinical
through to commercial product supply. These capabilities have been
established through the development of Ark's own products through
to Marketing Authorisation Application registered with the European
Medicines Agency. Following a change in business strategy in 2011,
Ark is now building its business through contract development and
manufacturing services and is seeking external partners to advance
those products it previously had under development.
Ark's shares were first listed on the London Stock Exchange in
March 2004 (AKT.L).
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's
financial position, business strategy, plans and objectives of
management for future operations (including development plans and
objectives relating to the Group's products and services), and any
statements preceded by, followed by or that include forward-looking
terminology such as the words "targets", "believes", "estimates",
"expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or
achievements of the Group to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could
cause the Group's actual results, performance or achievements to
differ materially from those in forward-looking statements include
those relating to Ark's funding requirements, regulatory approvals,
clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements
speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Group's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking
statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBKNDNPBDDQKD
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jul 2023 to Jul 2024